Abstract
Objective. Massive hemorrhage with shock is a common problem for the intensivist. The use of recombinant activated factor VII (rFVIIa), known as efficient treatment for hemophilia, has been reported to control severe bleeding episodes in critically care patients, but never in preterm neonates.
Design. Case report (two cases) and review of the literature.
Setting. Neonatal intensive care unit, university teaching hospital.
Patients. Two preterm neonates with life-threatening hemorrhages, from the liver and spleen in one patient and from the lung in the other.
Intervention. Intravenous administration of 150/200 µg/kg of rFVIIa (Novoseven, NovoNordisk, Copenhagen, Denmark).
Measurements and results. Complete hemostasis 10 min after the second bolus in the two patients.
Conclusion. For the intensivist, the successful use of rFVIIa in these patients and others lacking pre-existing coagulopathies points to rFVIIa as a novel therapeutic approach for patients presenting with massive life-threatening hemorrhage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Veldman, A., Fischer, D., Voigt, B. et al. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med 28, 1635–1637 (2002). https://doi.org/10.1007/s00134-002-1489-x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00134-002-1489-x